Aardvark Therapeutics, Inc. AARD

Procedural meeting confirms leadership continuity and financial oversight, but offers no new strategic or operational insights for investors.

Assessing unblinded Phase 3 HERO and OLE data for ARD-101 in PWS in the third quarter of 2026 to support an informed determination of next steps Remains in active discussions with the FDA to support resolution of the clinical hold for ARD-101 program $73.9 million in cash, cash equivalents and short-term investments as of June 30, 2026, supports projected operations into late 2027 SAN DIEGO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a

Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...

Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index falling 1.1% and

LanzaTech Global (LNZA) signed a securities purchase agreement with certain institutional investors

The company plans to unblind the late-stage study that was halted due to safety concerns, which could lead to an overhaul of its entire development program.

SAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has placed a full clinical hold on its investigational new drug application (IND) for ARD-101 related to the Company’s previously announced

ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026 $91.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, supports projected operations into mid-2027 SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabo

Over the last 7 days, the United States market has dropped 29%, and in the past year, it is down 82%, though earnings are forecast to grow by 16% annually. Despite these challenging conditions, identifying stocks with solid financials can still offer potential for growth. Penny stocks, often associated with smaller or newer companies, continue to present opportunities for investors seeking hidden value in quality companies. We've selected three examples that combine balance sheet strength...

Aardvark Therapeutics, Inc. (NASDAQ:AARD) is one of the penny stocks with potential to rise 1000 percent. Aardvark Therapeutics said on March 23, 2026, that it had voluntarily paused its Phase 3 HERO and open-label extension trials of ARD-101 in Prader-Willi syndrome, as well as the ARD-201 obesity program, while it works with the FDA on […]

Voluntary pause of the Phase 3 HERO and OLE trials evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi Syndrome, further guidance on the program expected in Q2 2026 ARD-201 obesity program, including POWER and STRENGTH trials, on voluntary pause pending next steps with ARD-101; further guidance on the program expected in Q2 2026 Clinical and preclinical data from ARD-101 program published in Molecular Metabolism $110.0 million in cash, cash equivalents and short-

Aardvark Therapeutics (AARD) has drawn investor attention after voluntarily pausing its Phase 3 HERO trial for ARD-101 in Prader-Willi Syndrome, following reversible cardiac observations at higher than target doses. See our latest analysis for Aardvark Therapeutics. The voluntary HERO trial pause and related analyst downgrades have coincided with sharp weakness in Aardvark Therapeutics’ share price, with a 7 day share price return of 54.44% and a year to date share price return of 57.24%,...

Aardvark Therapeutics recently paused its Phase 3 HERO trial of ARD-101 for Prader-Willi Syndrome after reversible cardiac-related observations emerged at above-target doses in a healthy volunteer study, delaying previously expected topline data timelines. The pause comes despite ARD-101 holding both Orphan Drug and Rare Pediatric Disease designations from the FDA for Prader-Willi Syndrome, underscoring the program’s regulatory importance and complexity. With the Phase 3 HERO trial on hold...

Health care stocks declined late Monday afternoon with the NYSE Health Care Index falling 1.2% and t

The detection of certain cardiac issues in a study of healthy volunteers led Aardvark to pause a Phase 3 trial only months before an expected data readout.

SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced it is voluntarily pausing the Phase 3 Hunger Elimination or Reduction Objective (HERO) trial. The HERO trial is a Phase 3 randomized, double-blind, placebo-controlled trial evaluating the efficacy and sa